Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Reaches New 1-Year Low at $52.25

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) hit a new 52-week low on Tuesday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares. The stock had previously closed at $52.25.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95. The company has a 50-day simple moving average of $51.83 and a 200-day simple moving average of $51.68. The stock has a market cap of $10.78 billion, a PE ratio of 18.80 and a beta of 0.33.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The business had revenue of $622.00 million during the quarter. Sell-side analysts anticipate that Recordati Industria Chimica e Farmaceutica S.p.A. will post 2.81 EPS for the current fiscal year.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.